The impact of anti-malarial markets on artemisinin resistance : perspectives from Burkina Faso
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Widespread artemisinin resistance in Africa could be catastrophic when drawing parallels with the failure of chloroquine in the 1970s and 1980s. This article explores the role of anti-malarial market characteristics in the emergence and spread of arteminisin resistance in African countries, drawing on perspectives from Burkina Faso.
METHODS: Data were collected through in-depth interviews and focus group discussions. A representative sample of national policy makers, regulators, public and private sector wholesalers, retailers, clinicians, nurses, and community members were purposively sampled. Additional information was also sought via review of policy publications and grey literature on anti-malarial policies and deployment practices in Burkina Faso.
RESULTS: Thirty seven in-depth interviews and 6 focus group discussions were conducted. The study reveals that the current operational mode of anti-malarial drug markets in Burkina Faso promotes arteminisin resistance emergence and spread. The factors are mainly related to the artemisinin-based combination therapy (ACT) supply chain, to ACT quality, ACT prescription monitoring and to ACT access and misuse by patients.
CONCLUSION: Study findings highlight the urgent requirement to reform current characteristics of the anti-malarial drug market in order to delay the emergence and spread of artemisinin resistance in Burkina Faso. Four recommendations for public policy emerged during data analysis: (1) Address the suboptimal prescription of anti-malarial drugs, (2) Apply laws that prohibit the sale of anti-malarials without prescription, (3) Restrict the availability of street drugs, (4) Sensitize the population on the value of compliance regarding correct acquisition and intake of anti-malarials. Funding systems for anti-malarial drugs in terms of availability and accessibility must also be stabilized.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Malaria journal - 22(2023), 1 vom: 13. Sept., Seite 269 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guissou, Rosemonde M [VerfasserIn] |
---|
Links: |
---|
Themen: |
886U3H6UFF |
---|
Anmerkungen: |
Date Completed 15.09.2023 Date Revised 23.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12936-023-04705-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM362022933 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM362022933 | ||
003 | DE-627 | ||
005 | 20231226090355.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12936-023-04705-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1206.xml |
035 | |a (DE-627)NLM362022933 | ||
035 | |a (NLM)37705004 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Guissou, Rosemonde M |e verfasserin |4 aut | |
245 | 1 | 4 | |a The impact of anti-malarial markets on artemisinin resistance |b perspectives from Burkina Faso |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.09.2023 | ||
500 | |a Date Revised 23.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
520 | |a BACKGROUND: Widespread artemisinin resistance in Africa could be catastrophic when drawing parallels with the failure of chloroquine in the 1970s and 1980s. This article explores the role of anti-malarial market characteristics in the emergence and spread of arteminisin resistance in African countries, drawing on perspectives from Burkina Faso | ||
520 | |a METHODS: Data were collected through in-depth interviews and focus group discussions. A representative sample of national policy makers, regulators, public and private sector wholesalers, retailers, clinicians, nurses, and community members were purposively sampled. Additional information was also sought via review of policy publications and grey literature on anti-malarial policies and deployment practices in Burkina Faso | ||
520 | |a RESULTS: Thirty seven in-depth interviews and 6 focus group discussions were conducted. The study reveals that the current operational mode of anti-malarial drug markets in Burkina Faso promotes arteminisin resistance emergence and spread. The factors are mainly related to the artemisinin-based combination therapy (ACT) supply chain, to ACT quality, ACT prescription monitoring and to ACT access and misuse by patients | ||
520 | |a CONCLUSION: Study findings highlight the urgent requirement to reform current characteristics of the anti-malarial drug market in order to delay the emergence and spread of artemisinin resistance in Burkina Faso. Four recommendations for public policy emerged during data analysis: (1) Address the suboptimal prescription of anti-malarial drugs, (2) Apply laws that prohibit the sale of anti-malarials without prescription, (3) Restrict the availability of street drugs, (4) Sensitize the population on the value of compliance regarding correct acquisition and intake of anti-malarials. Funding systems for anti-malarial drugs in terms of availability and accessibility must also be stabilized | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a ACT | |
650 | 4 | |a Antimalarial market | |
650 | 4 | |a Artemisinin resistance | |
650 | 4 | |a Burkina Faso | |
650 | 4 | |a Malaria | |
650 | 7 | |a Antimalarials |2 NLM | |
650 | 7 | |a Chloroquine |2 NLM | |
650 | 7 | |a 886U3H6UFF |2 NLM | |
650 | 7 | |a Artemisinins |2 NLM | |
700 | 1 | |a Amaratunga, Chanaki |e verfasserin |4 aut | |
700 | 1 | |a de Haan, Freek |e verfasserin |4 aut | |
700 | 1 | |a Tou, Fatoumata |e verfasserin |4 aut | |
700 | 1 | |a Cheah, Phaik Yeong |e verfasserin |4 aut | |
700 | 1 | |a Yerbanga, R Serge |e verfasserin |4 aut | |
700 | 1 | |a Moors, Ellen H M |e verfasserin |4 aut | |
700 | 1 | |a Dhorda, Mehul |e verfasserin |4 aut | |
700 | 1 | |a Tindana, Paulina |e verfasserin |4 aut | |
700 | 1 | |a Boon, Wouter P C |e verfasserin |4 aut | |
700 | 1 | |a Dondorp, Arjen M |e verfasserin |4 aut | |
700 | 1 | |a Ouédraogo, Jean Bosco |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Malaria journal |d 2002 |g 22(2023), 1 vom: 13. Sept., Seite 269 |w (DE-627)NLM119307685 |x 1475-2875 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:13 |g month:09 |g pages:269 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12936-023-04705-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2023 |e 1 |b 13 |c 09 |h 269 |